{
  "drug_name": "Clarithromycin",
  "url": "https://wikem.org/wiki/Clarithromycin",
  "scraped_at": "2026-01-10T03:09:26.997123",
  "sections": {
    "General": {
      "text": "Type:\nMacrolide\nDosage Forms: 250, 500, 500ER; 125, 250/5ml\nCommon Trade Names: Biaxin, Biaxin XL",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Macrolide",
          "url": "https://wikem.org/wiki/Macrolide"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Infections,_bacterial": {
          "text": "250-500mg PO q12h x 7-14d\nAlt: 1000mg ER PO QD x 7-14d",
          "tables": []
        },
        "Chronic_bronchitis,_acute_bacterial_exacerbation": {
          "text": "1000mg ER PO q24 x 7d (with food, do not cut/crush/chew)\nAlt: 250-500mg PO q12h x 7-14d",
          "tables": []
        },
        "Pharyngitis/tonsillitis,_streptococcal": {
          "text": "250mg PO q12h x 10d",
          "tables": []
        },
        "MAC_primary_prophylaxis": {
          "text": "500mg PO q12h",
          "tables": []
        },
        "MAC_secondary_prophylaxis,_HIV": {
          "text": "500mg PO q12h (use with ethambutol)",
          "tables": []
        },
        "MAC_treatment,_disseminated": {
          "text": "500mg PO q12h (use with ethambutol)",
          "tables": []
        },
        "H._pylori_infection": {
          "text": "triple treatment: 500mg PO q12hr x 7-14d\ndual treatment: 500mg PO q8h x 14d (give with Omeprazole 40mg QD x 14d)",
          "tables": []
        },
        "Endocarditis_prophylaxis,_dental": {
          "text": "500mg PO x1 (30-60min before procedure)",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "",
      "subsections": {
        "Infections,_bacteria": {
          "text": "> 6 months: 15mg/kg/day PO divided q12h, max 1000mg/day",
          "tables": []
        },
        "Otitis_media,_acute": {
          "text": "2mo-5yrs: 15mg/kg/day PO divided q12h x 10d\n6-12yrs: 15mg/kg/day PO divided q12 x 5-10d",
          "tables": []
        },
        "Pharyngitis/tonsillitis,_streptococcal_2": {
          "text": ">6mo: 15mg/kg/day PO divided q12h x 7-10d",
          "tables": []
        },
        "MAC_primary_prophylaxis,_HIV_patients": {
          "text": "20mo-12yrs: 15mg/kg/day PO divided q12h; max 500mg/dose\n>13yrs: 500mg PO q12h",
          "tables": []
        },
        "MAC_secondary_prophylaxis,_HIV_patients": {
          "text": "20mo-12yrs: 15mg/kg/day PO divided q12h; max 500mg/dose (use with ethambutol)\n>13yrs: 500mg PO q12h (use with ethambutol)",
          "tables": []
        },
        "MAC_treatments": {
          "text": "20mo-12yrs: 15-30mg/kg/day PO divided q12h; max 500mg/dose (use with ethambutol)\n>13yrs: 500mg PO q12h (use with ethambutol)",
          "tables": []
        },
        "endocarditis_prophylaxis,_dental_2": {
          "text": "15mg/kg PO x1; max 500mg (30-60min before procedure)",
          "tables": []
        },
        "H._pylori_infection_2": {
          "text": "20mg/kg/day PO divided BID x 7-14d; max 1000mg/day",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy: C (risk cannot be ruled out)\nLactation: safety unknown\nRenal Dosing\nAdult\nall uses with out ritonavir or atazanavir\nGFR < 30: decrease dose 50% or give IR form q24h or ER form q48h\nHD/PD: no supplement\nconcomitant ritonavir or atazanavir\nGFR 30-60: decrease dose 50%\nGFR < 30: decrease dose 75%\nHD/PD: no supplement\nPediatric\nall uses without ritonavir or atazanavir\nGFR < 30: decrease dose 50% or give q24h\nHD/PD: no supplement\nconcomitant ritonavir or atazanavir\nnot defined\nHepatic Dosing\nAdult: no adjustment\nPediatric: no adjustment",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nLiver disease\nRenal disease\nprolonged QT\nventricular arrythmias or history of\nhistory of torsades de pointes\nuncorrected electrolyte abnormalities\nsignificant bradycardia\ncaution if recent MI\ncaution if CHF\ncaution in female and elderly\ncaution in myasthenia gravis\ncaution with digoxin co-administration",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "superinfection\nC-difficile-associated diarrhea\nhepatotoxicity\ninterstitial nephritis\npancreatitis\nQT prolongation\nventricular arrhythmias\ntorsades de pointes\nthrombocytopenia\nleukopenia\nneutropenia\nhearing loss, reversible\nseizures\nbehavioral disturbances\npsychosis\nhallucinations\npsychiatric disturbance\nanaphylaxis\nerythema multiforme\nStevens-Johnson Syndrome\ndrug rash with eosinophilia and systemic sx\nmyasthenia gravis exacerbation\nrhabdomyolysis",
          "tables": []
        },
        "Common": {
          "text": "diarrhea\nnausea and vomiting\ntaste changes\nabdominal pain\ndyspepsia\nheadache\nrash",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 3-4 hours (increased with dosage increase)\n[1]\nMetabolism: hepatic (rapid first-pass metabolism), CYP3A4\nExcretion: renal\nMechanism of Action: interferes with bacterial protein synthesis by binding to a component of the 50S subunit",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}